Details for Patent: 8,877,938
✉ Email this page to a colleague
Which drugs does patent 8,877,938 protect, and when does it expire?
Patent 8,877,938 protects ENTRESTO SPRINKLE and ENTRESTO and is included in two NDAs.
Protection for ENTRESTO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has seventy-two patent family members in thirty-five countries.
Summary for Patent: 8,877,938
| Title: | Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
| Abstract: | A compound of an angiotensin receptor antagonist (ARB), a neutral endopeptidase inhibitor (NEPi) and one or more monovalent cations are useful for the treatment of hypertension and/or heart failure. ARB includes S--N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-v- aline in the anion form, NEPi includes (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in the anion form and cation includes monovalent cations such as Na.sup.+. The compound includes trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propi- onate-(S)-3'-methyl-2'-(pentanoyl{2''-(tetrazol-5-ylate)biphenyl-4'-ylmeth- yl}amino)butyrate] hemipentahydrate. |
| Inventor(s): | Feng; Lili (Pine Brook, NJ), Godtfredsen; Sven Erik (Chatham, NJ), Hu; Bin (Green Brook, NJ), Liu; Yugang (Bridgewater, NJ), Karpinski; Piotr (Lincoln Park, NJ), Sutton; Paul Allen (Parsippany, NJ), Prashad; Mahavir (Montville, NJ), Girgis; Michael J. (Montville, NJ), Blacklock; Thomas J. (Clark, NJ) |
| Assignee: | Novartis Pharmaceuticals Corporation (East Hanover, NJ) |
| Application Number: | 11/722,360 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,877,938 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; |
More… ↓ |
Drugs Protected by US Patent 8,877,938
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | ENTRESTO SPRINKLE | sacubitril; valsartan | CAPSULE, PELLETS;ORAL | 218591-001 | Apr 12, 2024 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
| Novartis | ENTRESTO SPRINKLE | sacubitril; valsartan | CAPSULE, PELLETS;ORAL | 218591-002 | Apr 12, 2024 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
| Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-001 | Jul 7, 2015 | AB | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,877,938
| PCT Information | |||
| PCT Filed | November 08, 2006 | PCT Application Number: | PCT/US2006/043710 |
| PCT Publication Date: | May 18, 2007 | PCT Publication Number: | WO2007/056546 |
International Family Members for US Patent 8,877,938
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1948158 | ⤷ Subscribe | 16C0018 | France | ⤷ Subscribe |
| European Patent Office | 1948158 | ⤷ Subscribe | 300810 | Netherlands | ⤷ Subscribe |
| European Patent Office | 1948158 | ⤷ Subscribe | PA2016017 | Lithuania | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
